FDA Approves Cetuximab, FOLFIRI Combo for KRAS-negative Colorectal Cancer

Share this content:
(ChemotherapyAdvisor) – The United States Food and Drug Administration (FDA) approved cetuximab for first-line treatment of patients with KRAS mutation-negative epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), according to a July 6 joint press release from Eli Lilly and Company (Indianapolis, IN) and Bristol-Myers Squibb (New York, NY).

According to the press release, this is the first and only FDA-approved, biomarker-directed therapy for a specific subset of newly diagnosed EGFR-expressing metastatic colorectal cancer (mCRC) patients, targeting those with KRAS mutation-negative tumors. A companion diagnostic kit for the detection of the KRAS mutation has been concurrently approved by the FDA.

“The new indication is based on data from the CRYSTAL (Cetuximab combined with iRinotecan in first-line therapY for metaSTatic colorectAL cancer) trial, a phase 3, open label, randomized, multicenter study conducted outside the United States,” the company wrote.

The positive CRYSTAL study, with progression-free survival (PFS) as the primary end point, involved the randomization of the patient population treated with EU-approved cetuximab plus FOLFIRI (the CRYSTAL regimen) vs FOLFIRI alone.

ERBITUX®, which is the form of cetuximab approved in the United States, provides approximately 22% higher exposure relative to the EU-approved cetuximab. Taken together, pharmacokinetic data, the results of the CRYSTAL trial, and other clinical trial data, it was possible for the drug manufacturers to establish the efficacy of ERBITUX at the recommended dose in combination with FOLFIRI for first-line KRAS mutation-negative (wild-type) EGFR-expressing mCRC.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs